Algert Global LLC Purchases 22,792 Shares of RxSight, Inc. (NASDAQ:RXST)

Algert Global LLC boosted its stake in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 55.1% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 64,148 shares of the company's stock after purchasing an additional 22,792 shares during the period. Algert Global LLC owned about 0.17% of RxSight worth $3,171,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CWM LLC grew its position in RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company's stock valued at $25,000 after purchasing an additional 371 shares in the last quarter. Nisa Investment Advisors LLC grew its position in RxSight by 854.1% during the third quarter. Nisa Investment Advisors LLC now owns 582 shares of the company's stock valued at $29,000 after purchasing an additional 521 shares in the last quarter. Quest Partners LLC purchased a new position in RxSight during the second quarter valued at approximately $41,000. Amalgamated Bank grew its position in RxSight by 21.3% during the second quarter. Amalgamated Bank now owns 1,177 shares of the company's stock valued at $71,000 after purchasing an additional 207 shares in the last quarter. Finally, KBC Group NV lifted its stake in RxSight by 63.6% in the third quarter. KBC Group NV now owns 1,232 shares of the company's stock valued at $61,000 after acquiring an additional 479 shares during the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Oppenheimer reduced their target price on shares of RxSight from $72.00 to $65.00 and set an "outperform" rating for the company in a research note on Tuesday, August 6th. Stifel Nicolaus reduced their target price on shares of RxSight from $70.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, August 6th. Wells Fargo & Company reduced their target price on shares of RxSight from $68.00 to $54.00 and set an "overweight" rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC reiterated a "buy" rating and issued a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. Finally, Jefferies Financial Group assumed coverage on shares of RxSight in a research note on Tuesday, October 29th. They issued a "buy" rating and a $72.00 target price for the company. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $61.63.

RxSight Trading Down 0.7 %

NASDAQ:RXST traded down $0.32 during trading hours on Tuesday, hitting $46.06. 226,427 shares of the company traded hands, compared to its average volume of 488,739. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -55.41 and a beta of 1.19. RxSight, Inc. has a twelve month low of $28.88 and a twelve month high of $66.54. The firm has a 50-day moving average of $49.20 and a 200 day moving average of $52.57.

Insider Activity at RxSight

In other RxSight news, insider Ilya Goldshleger sold 3,100 shares of the business's stock in a transaction on Friday, September 20th. The shares were sold at an average price of $53.19, for a total value of $164,889.00. Following the sale, the insider now owns 42,246 shares of the company's stock, valued at $2,247,064.74. The trade was a 6.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jesse Anderson Corley purchased 11,111 shares of the stock in a transaction on Tuesday, November 12th. The stock was acquired at an average cost of $45.37 per share, for a total transaction of $504,106.07. Following the acquisition, the director now directly owns 468,571 shares in the company, valued at approximately $21,259,066.27. This trade represents a 2.43 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 52,720 shares of company stock worth $2,603,950 in the last ninety days. 9.36% of the stock is currently owned by insiders.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.